Gossamer Bio (GOSS) Current Deferred Revenue (2024 - 2026)
Gossamer Bio (GOSS) posted quarterly Current Deferred Revenue of $8.7 million for Q1 2026, down 83.97% year-over-year from $54.5 million in Q1 2025, and down 56.27% quarter-over-quarter from $20.0 million in Q4 2025.
Gossamer Bio (GOSS) Current Deferred Revenue (2024 - 2026) Analysis & Trends
Gossamer Bio's Current Deferred Revenue history runs 3 years deep, the most recent figure standing at $8.7 million for Q1 2026.
- In Q1 2026, Current Deferred Revenue fell 83.97% year-over-year to $8.7 million; the TTM figure through Mar 2026 stood at $8.7 million (down 83.97% YoY), while the FY2025 annual figure was $20.0 million, down 64.26% from the prior year.
- Current Deferred Revenue for Q1 2026 stood at $8.7 million, down from $20.0 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $66.7 million in Q2 2024, with the low at $8.7 million in Q1 2026.
- The 3-year median for Current Deferred Revenue is $39.3 million (2025), against an average of $39.7 million.
- The sharpest annual moves came in 2025 and 2026: Current Deferred Revenue plunged 62.56% in 2025, then plunged 83.97% in 2026.
- Gossamer Bio's Current Deferred Revenue stood at $55.9 million in 2024, then sank by 64.26% to $20.0 million in 2025, then sank by 56.27% to $8.7 million in 2026.
- Business Quant data shows GOSS's Current Deferred Revenue at $8.7 million in Q1 2026, $20.0 million in Q4 2025, and $24.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Gossamer Bio | 49.15 Mn | -7.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.10 Mn |
| Mar 31, 2026 | 8.74 Mn |
| Dec 31, 2025 | 19.99 Mn |
| Sep 30, 2025 | 24.00 Mn |
| Jun 30, 2025 | 23.50 Mn |
| Mar 31, 2025 | 54.54 Mn |
| Dec 31, 2024 | 55.92 Mn |
| Sep 30, 2024 | 64.11 Mn |
| Jun 30, 2024 | 66.70 Mn |